Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation - Poll - MDSpire

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation

  • By

  • Caroline Foxton

  • Bradley Waldron

  • Alexander Wurzer

  • Calogero D’Alessandria

  • Alfred Morgenstern

  • Frank Bruchertseifer

  • Tea Kirkegaard Nielsen

  • Rikke Veggerby Grønlund

  • Mathias Wikke Hallund

  • Daniel J. Stevens

  • July 16, 2026

Share

Original Source(s)

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation

  • by Caroline Foxton, Bradley Waldron, Alexander Wurzer, Calogero D’Alessandria, Alfred Morgenstern, Frank Bruchertseifer, Tea Kirkegaard Nielsen, Rikke Veggerby Grønlund, Mathias Wikke Hallund, Daniel J. Stevens

  • July 16, 2026

Related Content

Non-metastatic pediatric head and neck rhabdomyosarcoma: a 24-year retrospective experience from Jordan

Combined therapy strategies of immune checkpoint inhibitors in gynecologic oncology: progress and challenges

Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice